Portola Pharmaceuticals Inc. (PTLA)

27.65
0.22 0.80
NASDAQ : Health Technology
Prev Close 27.43
Open 27.28
Day Low/High 26.92 / 27.69
52 Wk Low/High 14.81 / 37.95
Volume 182.57K
Avg Volume 1.07M
Exchange NASDAQ
Shares Outstanding 76.36M
Market Cap 2.05B
EPS -5.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of November 15th Options Trading For Portola Pharmaceuticals (PTLA)

First Week Of November 15th Options Trading For Portola Pharmaceuticals (PTLA)

Investors in Portola Pharmaceuticals, Inc. saw new options become available this week, for the November 15th expiration.

Portola Pharmaceuticals Appoints Ted W. Love, M.D., To Its Board Of Directors

Portola Pharmaceuticals Appoints Ted W. Love, M.D., To Its Board Of Directors

SOUTH SAN FRANCISCO, Calif., Sept.

Portola Pharmaceuticals To Participate In Two Upcoming Investor Conferences

Portola Pharmaceuticals To Participate In Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug.

Portola Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Portola Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

SOUTH SAN FRANCISCO, Calif., Aug.

Portola Pharmaceuticals Announces Proposed Offering Of Common Stock

Portola Pharmaceuticals Announces Proposed Offering Of Common Stock

SOUTH SAN FRANCISCO, Calif., Aug.

Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results And Provides Corporate Update

Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results And Provides Corporate Update

- Second Quarter Revenues of $28.4 Million; Andexxa® Net Product Revenues Grow to $27.1 Million -

Portola Launches European Sales Of Ondexxya® (Andexanet Alfa) With First Orders In Europe

Portola Launches European Sales Of Ondexxya® (Andexanet Alfa) With First Orders In Europe

- Expands Patient Access to the First and Only Factor Xa Reversal Agent Approved in Europe for Life-Threatening Bleeds Associated with the Use of Rivaroxaban or Apixaban -

U.S. Centers For Medicare And Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement For Portola Pharmaceuticals' Andexxa

U.S. Centers For Medicare And Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement For Portola Pharmaceuticals' Andexxa

- Add-on Payment Increased from 50 to 65 Percent; Supports Patient Access by Providing Additional Medicare Reimbursement in the Hospital Setting -

Portola Pharmaceuticals To Announce Second Quarter 2019 Financial Results On Wednesday, August 7, 2019

Portola Pharmaceuticals To Announce Second Quarter 2019 Financial Results On Wednesday, August 7, 2019

SOUTH SAN FRANCISCO, Calif., July 17, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals Presents New In Vitro Data Demonstrating That Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect On Inhibition Of Thrombin Generation By Factor Xa Inhibitors

Portola Pharmaceuticals Presents New In Vitro Data Demonstrating That Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect On Inhibition Of Thrombin Generation By Factor Xa Inhibitors

- Data Presented at the Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH 2019) -

Portola Pharmaceuticals Presents New In Vitro Data Demonstrating That Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect On Inhibition Of Thrombin Generation By Factor Xa Inhibitors

Portola Pharmaceuticals Presents New In Vitro Data Demonstrating That Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect On Inhibition Of Thrombin Generation By Factor Xa Inhibitors

- Data Presented at the Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH 2019) -

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

Portola Presents New Interim Data On Its Oral SYK/JAK Inhibitor Cerdulatinib In Heavily Pre-Treated Patients With Relapsed/Refractory Follicular Lymphoma

Portola Presents New Interim Data On Its Oral SYK/JAK Inhibitor Cerdulatinib In Heavily Pre-Treated Patients With Relapsed/Refractory Follicular Lymphoma

- Interim Phase 2a Data Highlight Efficacy and Safety Results of Cerdulatinib Alone and in Combination with Rituximab -

JPMorgan Chase, VF Corp., Anadarko Petroleum: 'Mad Money' Lightning Round

JPMorgan Chase, VF Corp., Anadarko Petroleum: 'Mad Money' Lightning Round

Jim Cramer weighs in on JPMorgan Chase, VF Corp., Anadarko Petroleum, Okta, Portola Pharmaceuticals, JD.com and more.

What You Need to Watch: Cramer's 'Mad Money' Recap (Thursday 4/4/19)

What You Need to Watch: Cramer's 'Mad Money' Recap (Thursday 4/4/19)

Jim Cramer warns: Don't blink or you'll miss this market movement. He looks at what's got investors' attention: Boeing, China, retailers and rotations.

Interesting PTLA Put And Call Options For September 20th

Interesting PTLA Put And Call Options For September 20th

Investors in Portola Pharmaceuticals, Inc. saw new options become available this week, for the September 20th expiration.

Interesting PTLA Put And Call Options For February 15th

Interesting PTLA Put And Call Options For February 15th

Investors in Portola Pharmaceuticals, Inc. saw new options become available this week, for the February 15th expiration.

3 Small Biotechs That Came Up Big on Thursday

3 Small Biotechs That Came Up Big on Thursday

Portola Pharmaceuticals, Flexion Therapeutics and BioDelivery Sciences delivered nice third-quarter numbers.

First Week Of June 2019 Options Trading For Portola Pharmaceuticals (PTLA)

First Week Of June 2019 Options Trading For Portola Pharmaceuticals (PTLA)

Investors in Portola Pharmaceuticals, Inc. saw new options become available this week, for the June 2019 expiration.

First Week Of November 16th Options Trading For Portola Pharmaceuticals (PTLA)

First Week Of November 16th Options Trading For Portola Pharmaceuticals (PTLA)

Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the November 16th expiration.

First Week Of January 2021 Options Trading For Portola Pharmaceuticals (PTLA)

First Week Of January 2021 Options Trading For Portola Pharmaceuticals (PTLA)

Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the January 2021 expiration.

Insider Buys of 2 Down Stocks Catch My Eye

Insider Buys of 2 Down Stocks Catch My Eye

Big insider purchases at Portola Pharmaceuticals and Alta Mesa Resources could be revealing.

Interesting PTLA Put And Call Options For October 19th

Interesting PTLA Put And Call Options For October 19th

Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the October 19th expiration.

Diamondback Energy, Illinois Tool Works, Xerox: 'Mad Money' Lightning Round

Diamondback Energy, Illinois Tool Works, Xerox: 'Mad Money' Lightning Round

Jim Cramer weighs in on Diamondback Energy, Illinois Tool Works, Xerox, PetMed Express, STMicroelectronics, Booking and more.

Time to Cool Off: Cramer's 'Mad Money' Recap (Friday 5/11/18)

Time to Cool Off: Cramer's 'Mad Money' Recap (Friday 5/11/18)

Upcoming earnings? Optimistic spin on trade? Tech rally? Jim Cramer's got the game plan for next week and he tells investors to keep their cool.

Noteworthy Monday Option Activity: PTLA, W, EHTH

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Portola Pharmaceuticals, Inc. , where a total of 6,062 contracts have traded so far, representing approximately 606,200 underlying shares.

First Week Of December 21st Options Trading For Portola Pharmaceuticals (PTLA)

Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the December 21st expiration.

TheStreet Quant Rating: D- (Sell)